Access to Information Requests Completed - April 2013

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the month of April 2013

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2010-00562	Documents related to prebiotics (inulin, galacto-oligosaccharides, polydextrose) and probiotics (B.lactis, Lactobacillus GG) in infant formula. (Jan 1, 2008 to Aug 4, 2010).	Disclosed in part	903
A-2011-00381	All documents at Health Canada headquarters about media requests related to energy drinks or pre-mixed alcoholic beverages branded as pre-mixed energy drinks. (May 15 2010 to Jun 15, 2011).	Disclosed in part	2,530
A-2011-00920	The estimates, studies, analyses and briefing notes on the impact on Canada of the European Union's proposals concerning pharmaceuticals in the Comprehensive Economic and Trade Agreement (CETA) Intellectual Property chapter. (Jan 1, 2009 to Oct 26, 2011).	Disclosed in part	268
A-2011-01432	Information regarding the product C.F.S.S. Formula, NPN 02059894 by Douglas Laboratories Inc.	Disclosed in part	33
A-2011-01594	Information regarding the product Kivexa by GlaxoSmithKline Shire Biochem.	Disclosed in part	32
A-2012-00193	All documents from the Assistant Deputy Minister level and above regarding the government's decision to close Assisted Human Reproduction Canada effective March 1, 2013. (Mar 1, 2012 to Apr 1 2012).	Disclosed in part	17
A-2012-00336	All documents pertaining to requests for special access to diacetylmorphine (heroin) or hydromorphyne (Dilaudid) for participants in the NAOMI (North American Opiate Medication Initiative) research study. (Jan 1, 2005 to May 4, 2012).	Disclosed in part	311
A-2012-00814	All documents related to Financial Management, budgeting and accounting of the Health Canada Wind Turbine Noise and Health Study. (Jan 1, 2011 to Aug 8, 2012).	Disclosed in part	149
A-2012-00824	All documents covering the period up to August 10, 2012 related to the visit to Canada by the United Nations Special Rapporteur on the right to food.	Disclosed in part	710
A-2012-00845	Documents produced in 2012 concerning the sale/export of counterfeit medicine/prescription drugs.	Disclosed in part	58
A-2012-00918	AER for the product Adalat XL. Report number: 000428019.	Disclosed in part	21
A-2012-01080	All documents regarding a review of the science around the process of mechanically tenderizing beef. (Sep 3, 2012 to Oct 6, 2012).	Disclosed in part	13
A-2012-01157	All email correspondence related to the safety of Opiods. (Jan 1, 2010 to Nov 22, 2012).	Disclosed in part	2,245
A-2012-01249	Documentation regarding the outcome of the 2011 Consultation on the Proposed Improvements to the Marihuana Medical Access Program.	Disclosed in part	479
A-2012-01319	Information regarding stakeholders 7 committees working to commercial growers of marihuana, any proposals regarding: Opportunity for those interested in becoming a licensed commercial producer.	Disclosed in part	150
A-2012-01345	Information regarding the product Colgate Sensitive Pro-Relief Mouthwash, NPN 80035527.	Disclosed in part	83
A-2012-01347	The Bioequivalence information regarding the product Novo-mycophénolate (250 et 500 mg).	Disclosed in part	207
A-2012-01354	Information regarding the medical device HIGH PRESSURE SYRINGE KIT, License number 88813 by Shenzhen Ant Hi-Tech Industrial Co., Ltd.	Disclosed in part	21
A-2012-01356	Information regarding the medical device PRESSURE CONNECTING TUBE, License number 88995 by Shenzhen Ant Hi-Tech Industrial Co., Ltd.	Disclosed in part	21
A-2012-01382	All documents regarding the Adverse Reaction Reports for the product Naproxen. (Jan 1, 2009 to Jan 21, 2013).	Disclosed in part	67
A-2012-01383	All documents regarding the Adverse Reaction Reports for the product Toradol. (Jan 1, 2009 to Jan 21, 2013).	Disclosed in part	4
A-2012-01481	AERs for the product Cipralex. Report numbers: 000457897, 000458511, 00045878, 000459432, 000462178, 000463555, 000464066 and 00046488.	Disclosed in part	12
A-2012-01562	Any document showing the total costs spent annually who have undergone training on either of the following types of harassment: physical harassment, sexual harassment or verbal harassment. (Jan 1, 2005 to Feb 9, 2013).	All disclosed	2
A-2012-01610	Report # 4 of the Natural Health Products Program Advisory Committee. It concerns natural health products for weight loss or weight management.	All exempted	0
A-2012-01665	AER for the product Adalat XL. Report number: 000467079.	Disclosed in part	1
A-2012-01666	AERs for the product Avelox. Report numbers: 000460429, 000461911 and 000466492.	Disclosed in part	3
A-2012-01667	AERs for the product Cipro. Report numbers: 000461395, 000462134 and 000463336.	Disclosed in part	4
A-2012-01668	AER for the product Gadovist. Report number: 000461932.	Disclosed in part	1
A-2012-01669	AER for the product Glucobay. Report number: 000461475.	Disclosed in part	1
A-2012-01670	AERs for the product Mirena. Report numbers: 000462416, 000462661, 000463439 and 000464523.	Disclosed in part	4
A-2012-01671	AER for the product Visanne. Report number: 000465879.	Disclosed in part	1
A-2012-01676	All call-ups processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of February 2013.	Disclosed in part	26
A-2012-01677	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during February 2013.	All disclosed	2
A-2012-01691	All documents created for or by the Non-Insured Health Benefits (NIHB) Program's Drug Use Evaluation Advisory Committee (DUEAC) regarding benzodiazepines.	Disclosed in part	137
A-2012-01710	The overall number of Licenses of Production Sites to Produce Cannabis (marihuana) that have been issued by Health Canada under the Marihuana Medical Access Program to recipients within the City of Burnaby, British Columbia.	All disclosed	1
A-2012-01715	All documents submitted by Light Force Canada that pertains to any claims of efficacy in the therapeutic application of the Light Force Therapy. (The light from these panels was used to treat a variety of ailments including diabetic ulcers and arthritic joints).	Disclosed in part	18
A-2012-01716	AER for the product Lipidil AR. Report number: 000462664.	Disclosed in part	5
A-2012-01717	AERs for the product Biaxin AR. Report numbers: 000452619 and 000466117.	Disclosed in part	4
A-2012-01727	AERs for the product Lamotrigin. (Jan 1, 2010 to Mar 15, 2013).	No records exist	0
A-2012-01731	AER for the product Adalat XL. Report number: 000473680.	Disclosed in part	1
A-2012-01732	AERs for the product Avelox. Report numbers: 000468034, 000468296, 000468613, 000470067, 000472659 and 000472906.	Disclosed in part	8
A-2012-01733	AERs for the product Gadovist. Report numbers: 000468582, 000469685 and 000474022.	Disclosed in part	3
A-2012-01734	AERs for the product Mirena. Report numbers: 000467984, 000472886, 000473374, 000473549 and 000474070.	Disclosed in part	12
A-2012-01736	AER for the product Visanne. Report number: 000467384.	Disclosed in part	1
A-2012-01737	AER for the product Xarelto. Report number: 000470645.	Disclosed in part	1
A-2012-01738	AER for the product Yaz. Report number: 000469617 and 000474617.	Disclosed in part	2
A-2012-01741	The overall numbers of Production Sites that have been authorized to Produce Cannabis (marihuana) by Health Canada under the Marihuana Medical Access Program within the District of Mission, British Columbia.	Disclosed in part	17
A-2012-01742	All Cannabinoid-based research that has been conducted by Health Canada and the Federal Government. (Jan 1, 2007 to Mar 18, 2013).	No records exist	0
A-2012-01743	Information regarding the medical device PREVU NON-INVASIVE SKIN CHOLESTEROL POINT OF CARE (POC) TEST (PREVU POC TEST), License number 88163.	No records exist	0
A-2012-01749	Documents that indicate which carpet tile style name / number and manufacturer's name that was selected for the Laboratory Centres for Disease Control projects.	All disclosed	1
A-2012-01752	AER for the product Multaq. Report number: 000472418.	Disclosed in part	5
A-2012-01753	All emails between the Minister and government agencies / provinces / Centres for Disease Control and Prevention (Atlanta) and physicians as it relate to Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome. (Jan 1 2010 to Mar 22, 2013).	No records exist	0
A-2012-01756	AERs for the product Champix. Report numbers: 000329168, 000304387, 000308360, 000311644, 000313244, 000326768, 000331363, 000332894, 000349185, 000359220 and 000366091.	Disclosed in part	34
A-2012-01759	Copies of Consumer Product Complaints with respect to incidents involving glass cookware suddenly fracturing and causing personal injuries. (Jan 1, 1982 to Mar 25, 2013).	Disclosed in part	21
A-2012-01761	Document showing how many orders (number and dollars), in total, have been attributed to the providers selected on the basis of the invitation to tender No. 1000116856 of Health Canada. (Apr 1, 2011 to Mar 31, 2012).	All disclosed	1
A-2012-01763	All correspondence between Health Canada and Sea Delight regarding CO (carbon monoxide) also know as 'tasteless smoke' to treat seafood.	No records exist	0
A-2012-01765	Documents relating to the Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology (SAC-PSCP) meetings in December 2012, to consider further the meaning of identical medicinal ingredient.	All disclosed	11
A-2013-00006	Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during March 2013.	All disclosed	2
A-2013-00010	The investigation procedures that are used to verify that an applicant is legitimate, has a medical necessity for growing Marihuana and has no criminal record.	No records exist	0
A-2013-00011	The security procedures to ensure that growers do not grow more than the amount stated in their application.	No records exist	0